Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735211 | 0.90 | KCNH2 (0.42) | FFAR4KCNH2 | |
| SCHEMBL5736335 | 0.90 | FFAR4 (0.35) | FFAR4KCNH2 | |
| SCHEMBL5737291 | 0.80 | FFAR4 (0.35) | FFAR4KCNH2 | |
| SCHEMBL5738643 | 0.78 | LSS (0.34) | FFAR4KCNH2 | |
| SCHEMBL5735289 | 0.76 | SLC6A4 (0.32) | FFAR4KCNH2 | |
| SCHEMBL5733991 | 0.75 | KCNH2 (0.37) | FFAR4KCNH2 | |
| SCHEMBL5735408 | 0.74 | LSS (0.43) | FFAR4 | |
| SCHEMBL5737559 | 0.69 | KCNH2 (0.46) | FFAR4KCNH2 | |
| SCHEMBL5734945 | 0.69 | FFAR4 (0.35) | FFAR4KCNH2 | |
| SCHEMBL5736588 | 0.69 | KCNH2 (0.46) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349833-B1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1349833-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002044149-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | FFAR4 1018/4885KCNH2 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.